natgillin/translations-raw huggingface dataset:
The multispecific antigen-binding molecule of claim 3, wherein the antigen-binding site of the first polypeptide comprises an antigen-binding site which comprises H chain CDRs consisting of any one of the amino acid sequences selected from the following (a1) to (a11), or an antigen-binding site functionally equivalent thereto, and the antigen-binding site of the second polypeptide comprises an antigen-binding site which comprises H chain CDRs consisting of any one of the amino acid sequences selected from the following (b1) to (b11), or an antigen-binding site functionally equivalent thereto: 
mjesto vezanja antigena prvog polipeptida obuhvaća mjesto vezanja antigena koje obuhvaća H-lanac CDR-područja koji se sastoji od bilo koje od aminokiselinskih sekvenci odabranih od sljedećih (a1) do (a11), a mjesto vezanja antigena drugog polipeptida obuhvaća mjesto vezanja antigena koje obuhvaća H-lanac CDR-područja koji se sastoji od bilo koje od aminokiselinskih sekvenci odabranih od sljedećih (b1) do (b11):
The depots are typically made by means of a syringe or by use of a cytoscope or catheter. 
Tipično je da se odlaganja rade pomoću šprice ili korištenjem cistoskopa ili katetera.
The antibody of claim 1, wherein the antibody is ALULA (the antibody produced by the hybridoma as deposited under ATCC Deposit No. 
Protutijelo koje se specifično veže na avfB5 integrin, naznačeno time, da je protutijelo u humaniziranom obliku od protutijela proizvedenog od hybridoma deponiranog kao ATCC Depozit Br.
The bispecific single chain antibody of any of claims 1 to 9, wherein at least one of said first or second binding domains is chimeric, humanized, CDR-grafted, and/or deimmunized or human. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 14, naznačen time što je najmanje jedna od navedene prve ili druge vežuće domene kimerna, ljudskiizirana, nazađena s CDR-om i/ili deimunizirana ili ljudska.
When the solution has been completed, it is filtered through a heat-isolated sintered glass filter, keeping the temperature at 55-60°C. 
Kada se dobije otopina, filtrira se kroz toplinski izoliran filtar od sinteriranog stakla, održavajući temperaturu pri 55-60C.
According to one embodiment of the invention, the phosphate ions are added to said AlOOH/HBsAg complex before the mixing with the Hib antigen. 
Postupak prema jednom od prethodnih zahtjeva, naznačen time da se u navedeni A&IOOH/HBsAg kompleks dodaju fosfatni ioni prije miješanja s Hib antigenom.
In another embodiment, X is a post-translational signal peptide. In another embodiment, X is selected from the group consisting of the signal sequence from FlgI, NadA and pelB. 
Fuzijski protein u skladu s patentnim zahtjevom 1, naznačen time što je X signalni peptid iz proteina koji se bira iz skupine koju čine Flgl, NadA i pelB.
As already mentioned, it is advantageous to provide a service machinery space 22 separated from the refrigerated space 21 and which contains the movement system 5, the cooling system 6 and the processing system 7 . 
Kao što je već navedeno, poželjno je da se predvidi prostor 22 za strojeve koji služe za posluživanje, koji prostor je odvojen od prostora koji se hladi 21, i koji sadržava sustav za pomicanje 5, sustav za hlađenje 6 i sustav za obradu 7.
Strontium-82/rubidium-82 generator, comprising a column filled with a cationic exchanger loaded with strontium-82, and having an inlet and an outlet, and a liquid medium, wherein parts of the column, inlet and outlet coming into contact with the liquid medium are iron-free, preferably metal-free. 
Generator Stroncij-82/Rubidij-82, naznačen time da sadrži kolonu ispunjenu sa kationskim izmjenjivačem ispunjenim sa stroncijem-82, i koji ima ulazni otvor i izlazni otvor, te tekući medij, pri čemu dijelovi kolone, ulazni i izlazni otvor koji dolaze u doticaj sa tekućim medijem su bez željeza, poželjno bez metala, pri čemu tekući medij je elucijski medij za rubidij-82, te je fiziološki pufer koji ima pH od 6-8.5, poželjno pH od 7-8, još poželjnije pH od 7.2-7.4, i pri čemu tekući medij je sterilizacijski medij, poželjno hipokloritna otopina.
The method of claim 13, wherein the specific activity of the ADAMTS13 protein in the culture medium is at least 600U per mg ADAMTS13 protein. 
Metoda u skladu s patentnim zahtjevom 13, pri čemu je specifična aktivnost ADAMTS13 proteina u mediju za kultiviranje najmanje 600 U po mg ADAMTS13 proteina.
A use of an electrochemical cell electrolyte according to any of claims 1 to 8 in an electrochemical cell comprising an anode, wherein the anode material is selected from the group comprising Li4Ti5O12, Li2Ti3O7, LixTiO2, TiO2, TiO2(OH)x and mixtures thereof. 
Upotreba elektrolita elektrokemijskog članka u skladu s bilo kojim od patentnih zahtjeva 1 do 8 u elektrokemijskom članku koji sadrži anodu, naznačena time što se materijal anode bira iz skupine koju čine LuTi5042, LbT130;, Li, TiOo, TiO,, TiOx (OH), i njihove smjese.
The pallet container of claim 7, further comprising a retrieval connector disposed in a base region of the internal container and having an attached retrieval fitting, wherein the blank panel for the base face of the internal container on a shorter rearward one of the lateral edges of the internal container has an overlapping strip defined by a width of approx. 100 mm to 200 mm and on a shorter front-side lateral edge of the internal container has an overlapping strip defined by a width of approx. 100 mm to 300 mm with the overlapping strip of the blank panel on the shorter front-side lateral edge of the internal container being centrically interrupted and provided with a clearance for accessing the retrieval fitting. 
Paletni spremnik prema patentnom zahtjevu 5, naznačen time što prazna ploča za stranu osnovice unutarnjeg spremnika od plastičnog materijala na kraćem stražnjem bočnom rubu unutrašnjeg spremnika ima preklopnu traku koja ima širinu od približno 100 mm do 200 mm, poželjno od približno 150 mm, i na kraćem prednjem bočnom rubu unutrašnjeg spremnika ima preklopnu traku koja ima širinu od približno 100 mm do 300 mm, poželjno od približno 200 mm, pri čemu je ova preklopna traka prekinuta u sredini i ima otvor za pristup priključku za pražnjenje.
A method for increasing the pH of an aqueous suspension containing from 48 to 62 vol. 
Postupak za povisivanje pH vodene suspenzije koja sadrži od 48 do 62 vol.
A formulation for use according to claim 9 or 10 wherein the macrocyclic lactone concentration is from 0.5% to 0.9% (w/v) and the levamisole concentration is from 15% to 25% (w/v). 
Formulacija za uporabu prema zahtjevu 9 ili 10, naznačena time, da je koncentracija makrocikličkog laktona od 0,5% do 0,9% (masa/volumen) i koncentracija levamisola je od 15% do 25% (masa/volumen).
R1' is as defined in respect of Formula II; 
’ je kao što je definirano u svezi s Formulom II;
Moreover both of the compositions possess several undesirable side effects. 
Čak štoviše oba sastava imaju nekoliko neželjenih nuspojava.
For the purpose of selecting a specific length of the transverse rims, each layer of strips may comprise at least two strips which extend in the extension of one another, each of said two strips being mutually coupled. 
Sustav kalupa u skladu s patentnim zahtjevom 9, pri čemu svaki sloj traka (15) obuhvaća najmanje dvije trake koje se produžuju u nastavku jedna na drugu, svaka od navedenih dviju traka je međusobno povezana,
Method of removal of calcium from hydrocarbon feedstock, as claimed in claim 1 or claim 2, wherein said mixing of step (a) of claim 1 is carried out vigorously for enabling said chemical compound to chelate the calcium. 
Metoda uklanjanja kalcija 12 ugljikovodične sirovine prema patentnom zahtjevu 1 ili 2, naznačen time da je navedeno miješanje iz koraka pod (a) provedeno snažno kako bi se omogućlio da navedeni kemijski spoj kelira kalcij.
two longitudinal bearing surfaces intended to slide along the rails of the device for guiding the plate, 
(30) za interakciju sa detektorom za prolaz ploče (32) uređaja.
The vaccine of the present invention is a combination of at least 2, preferably at least 3, more preferably at least 4, even more preferably at least 5, peptides derived from amino acid residues 150 to 170 and 205 to 225 of PCSK9 (SEQ ID No. 9). 
PATENTNI ZAHTJEVI Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje osam uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 150 do 170 od PCSK9 u skladu sa
A vascular filter device as claimed in claim 11, wherein at least some filter elements have eyelets and the holder is trained through the eyelets. 
Vaskularni uređaj za filtriranje prema patentnom zahtjevu 3, naznačen time što barem neki od filtarskih elemenata imaju ušice i što je držač (1005) provučen kroz ušice (1011).
flashing (10,15,19,23) the rich solvent bottoms stream in at least one reduced pressure stage to regenerate lean solvent and to produce an overhead product stream that is enriched in at least one absorbed component gas, wherein the reduced pressure stage comprises two or more flash vessels of which at least one is a surge vessel; 
fleširanje (jednokratno isparavanje) (10, 15, 19, 23) donje struje obogaćenog otapala u barem jednom stupnju pod sniženim pritiskom da bi se regeneriralo čisto otapalo i da bi se proizvela vršna struja produkta, koja je obogaćena barem jednim apsorbiranim komponentnim plinom, u čemu stupanj pod smanjenim pritiskom sadrži dvije ili više posuda za isparavanje, od kojih je barem jedna posuda sabirna;
The invention further provides a monoclonal anti-LGR5 antibody 88M1 produced by a hybridoma cell line having ATCC deposit number PTA-9342. 
(a) monoklonalno protutijelo 8$8M1 proizvedeno pomoću stanične linije hibridoma koji ima broj ATCC depozita pod oznakom PTA-9342; ili
A compound as claimed in claim 1 of formula (Ic): 
Spoj formule (Ic): (R) gdje
The freezing points of deionised water, deionised water with sugar replacement composition and deionised water with sugar were determined by Differential Scanning Calorimetry (DSC) in two separate experiments at a cooling rate of 1 °C/min. 
Ledište deionizirane vode s dodanom sastavinom koja zamjenjuje šećer i s dodanim šećerom mjereno je diferencijalnom skenirajućom kalorimetrijom (Differential Scanning Calorimetry, DSC) u dva odvojena pokusa pri brzini hlađenja od 1 *C/min.
A peptide consisting of the sequence LTFGDVVAV (SEQ ID No. 10). 
Peptid koji se sastoji od sekvence prema ID br.
means for loading the container of dehydrated organic material into the input end of the equilibration chamber; 
sredstvo (42) za utovar posude (38) dehidriranog organskog materijala u ulazni kraj (155) ekvilibracijske komore (150);
wherein X is selected from the group consisting of Glu, Lys and Cys; wherein the side chain of at least one residue X is conjugated to a lipophilic substituent having the formula: Z1, wherein Z1 is a lipophilic moiety conjugated directly to the side chain of X; or 
X28 je odabran od Ser, Lys i Arg; gdje je X odabran iz skupine koju čine Glu, Lys i Cys; pri čemu je bočni lanac od najmanje jednog ostatka X konjugiran na lipofilni supstituent koji ima sljedeću formulu: (1) Z', gdje Z! je lipofilni dio skupine konjugiran izravno na bočni lanac od X; ili (11)
A process for the preparation of a compound of formula (I): wherein X is halogen; Y is ZR1; Z is oxygen or sulphur; and R1 is C1-6 alkyl, C1-6 haloalkyl or C3-7 cycloalkyl; the process comprising: hydrogenating a compound of formula (II): 
naznačen time da X je halogen; Y je ZR!:Z je kisik ili sumpor; iR' je Cis alkil, C,.4 haloalkil ili C,.; cikloalkil; postupak so sastoji od: hidrogeniranja spoja formule (II): X ON
The process of claim 1, wherein at least one of an operating temperature and an operating pressure in the second reaction stage is greater than an operating temperature and an operating pressure of the first reaction stage. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da su najmanje jedna radna temperatura i radni tlak u drugom reakcijskom stupnju (22) veći od radne temperature i radnog tlaka prvog reakcijskog stupnja (14).
a polypeptide antigen selected from the group consisting of Enterococcus faecalis, Staphylococcus aureaus, Staphylococcus epidermis, Pseudomonas aeruginosa, Legionella pneumophila, Listeria monocytogenes, influenza virus, and parainfluenza virus polypeptide antigens; and 
(a) polipeptidni antigen koji se bira iz skupine koju čine polipeptidni antigeni iz bakterija Enterococcus faecalis, Staphylococcus aureaus, Staphylococcus epidermis, Pseudomonas aeruginosa, Legionella pneumophila, Listeria monocitogenes, virusa influence, te virusa parainfluence; i
wherein said C(1-5)alkyl is optionally substituted with one to two substituents independently selected from CONH2, —CN, and OH; or A3 and A4 may be taken together with their attached nitrogen to make a ring selected from the group consisting of 
di bÅ pri čemu spomenuti Cq. salkilj je po potrebi supstituiran sa jednim do dva supstituenata nezavisno izehranik od COOH, CONH., -CN, i OH; ii A? i A" mogu se uzeti zajedno sa njihovim vezanim dušikom da se dobije prsten izabran iz grupe koja 25
The system of claim 1 wherein said direct current for spinal stimulation ranges from about 2 ma to about 5mA for treatment of muscle tone in humans. 
Sustav sukladno zahtjevu 1 pri čemu je navedena istosmjerna struja za spinalnu stimulaciju opsega od otprilke 2 ma do otprilike SmA za terapiju mišićnog tonusa kod ljudi.
Accordingly, the invention is further directed to stabilized etanercept formulations having, at M3 or T2 or T4, no more than, on average, about 10,000 subvisible particles per mL having a size greater than 5 um. 
Kompozicija stabilizirana magnezij kloridom prema patentnom zahtjevu 5 koja ima, u prosjeku, ne više od 10 000 čestica ispod granice vidljivosti po mL, koje imaju veličinu veću od 5 um.
The method according to claim 13, wherein the anti-inflammatory drug is administered at a dose of 0.001-500 mg per single administration. 
Spoj FGF-18 za uporabu prema zahtjevu 13 ili zahtjevu 14, naznačen time što se protu-upalni lijek treba primijeniti u dozi od 0.001-500 me, ili poželjno 0.1-250 mg, ili poželjnije 0.5-150 mg po jednom davanju.
Atomiser according to one of the preceding claims, characterised in that the first and/or second locked state is not reversible, and/or that the pressurisation or atomisation is mechanically driven, in particular without propellant gas, preferably by spring power, and/or that the atomiser (1) is a portable inhaler, in particular for medicinal aerosol therapy. 
Raspršivač prema jednom od prethodnih zahtjeva, naznačen time, da prvo i drugo zakočeno stanje nije moguće vratiti nazad, i/ili da se stlačivanje ili raspršivanje provodi mehanički, posebno bez pogonskog plina, poželjno pomoću snage opruge, i/ili da je raspršivač (1) prenosivi inhalator, posebno za medicinsko aerosolno liječenje.
US 5,948,458 describes a method for the prevention of spoilage, rancidity or off-color in a liquid food product containing unsaturated lipids and fats caused by exposure of the liquid food product to ultraviolet light comprising the step of adding to said food product an ultraviolet absorbing effective amount of tricalcium phosphate. 
US 5.948.458 opisuje postupak za sprečavanje kvarenja, užeglosti ili obezbojenja kod tekućeg prehrambenog proizvoda koji sadržava nezasićene lipide i masnoće, uzrokovanog izlaganjem tekućeg prehrambenog proizvoda ultraljubičastom svjetlu, koji postupak sadržava korak dodavanja spomenutom prehrambenom proizvodu količine trikalcij fosfata koja je djelotvorna za apsorbiranje ultraljubičastog svjetla.
50 mL IN HCl was added and stirring was continued 1 hour. 
Dodano je 50 mL IN HCI i miješanje se nastavilo još 1 sat.
A compound of formula (II) 
Spoj formule (II) J
The oral suspension is generally simply imbibed. 
Oralna suspenzija se općenito lako pije.
A method according to any of the preceding claims, wherein the heterogeneous catalyst further comprises at least one element selected from the group consisting of Fe, Ni, Co, Cu, Cr, W, Mn, Mo, V, Sn, Zn, Si in an amount up to 20 % by weight, such as an amount up to 10 % by weight, preferably in an amount up to 5 % by weight, such as up to 2,5 % by weight. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu heterogeni katalizator nadalje obuhvaća barem jedan element odabran iz grupe koja se sastoji od Fe, Ni, Co, Cu, Cr, W, Mn, Mo, V, Sn, Zn, S1 u količini do 20 % prema težini, kao što je količina do 10 % prema težini, poželjno u količini do 5 % prema težini, kao što je do 2,5 % prema težini.
A manipulating inspection device according to claim 1, characterized in that the transverse track (3) is provided with two sliding trolleys arranged independently of each other. 
Manipulacijski inspekcijski uređaj u skladu s patentnim zahtjevom 1, naznačen time što poprečna tračnica (3) imaju dvoja klizna kolica smještena neovisno jedna o drugima.
A humanized monoclonal antibody having a heavy chain and a light chain comprising the amino acid sequences of SEQ ID NO:35 and SEQ ID NO:31, respectively. 
PATENTNI ZAHTJEVI Humanizirano protutijelo, naznačeno time što ima teški lanac i laki lanac, koji imaju aminokiselinske sljedove SEQ ID NO:35 odnosno SEQ ID NO:31.
A method for reducing or stopping bleeding in a patient suffering from uterine fibroids, the method comprising administering to the patient for at least one menstrual cycle a daily oral dosage ranging from about 5 mg to about 20 mg of 17a acetoxy-11B-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) tablet, wherein bleeding is reduced or stopped after the administration of ulipristal acetate for one menstrual cycle. 
Ulipristal acetat (17a-acetoksi-115-[4-N,N-dimetilamino-fenil)-19-norpregna-4,9-dien-3,20-dion) ili bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB-4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 za daljnju uporabu u prevenciji ili liječenju anemije u te bolesnice,
Ulipristal acetate, or any metabolite selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183, for use in reducing or stopping bleedings in a patient suffering from uterine fibroids according to claim 7 which is repeated once a year. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 7 u ponavljanju od jednom godišnje.
wherein R6 is selected from methyl, ethyl, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, methoxymethyl, trifluoromethyl and difluoromethyl and R1, R2, R3, R4, R5, R7, A, L1, W1, L2, m, n, k and x′ are as defined above for compounds of formula (I); and pharmaceutically acceptable salts and solvates thereof. 
(IC) pri čemu je Ry odabran od metila, etila, hidroksimetila, 1-hidroksietila, 2-hidroksietila, metoksimetila, trifluormetila 1 difluormetila te su R,, R2, Rs, Ra, Rs, Ry, A, Li, Wii, Lo, m, nj, ki x kao što su definirani u patentnom zahtjevu 1 za spojeve formule (1), njihovu farmaceutski prihvatljivu sol 1 solvat.
contains substantially no air particles (e.g. 
- < ne sadrži u biti udio zraka (na pr.
A disposable absorbent article as described in claims 1-2, characterised in that the impermeable back sheet is laminated to a nonwoven fabric of about 10 and 15 g/m2 and containing bicomponent core and sheath fibres, with the core containing about 80 to about 100% of poly-hydroxy-alcanoate and the sheath containing about 80 to 100% polypropylene. 
Upijajući proizvod za jednokratnu upotrebu u skladu s patentnim zahtjevima 1 do 2, naznačen time, da je nepropusni donji sloj laminiran na netkani materijal od oko 10 i 15 g/m2 i sadržava dvokomponentna vlakna s jezgrom i omotačem, pri čemu jezgra sadržava oko 80 do približno 100 % polihidroksialkanoata i omotač sadržava približno oko 80 do 100 % polipropilena.
Moreover, the arrangement of the suction cups shown in said apparatus is absolutely not adaptable to an apparatus with continuous feeding of the containers, especially to an apparatus in which the containers to be treated are positioned on a rotary carrousel. 
Osim toga, razmještaj usisnih čašica koji je prikazan u navedenom uređaju apsolutno nije prilagodljiv za uređaj s kontinuiranim dopremanjem spremnika, naročito za uređaj u kojemu se spremnici koji se trebaju uzeti u postupak stavljeni na rotirajući stroj.
The solid form of claim 1, which exhibits a weight loss of about 0.16% of the total sample weight upon heating from about 25 to about 120 °C. 
Čvrsti oblik prema zahtjevu 1, naznačen time što pokazuje gubitak težine od oko 0.16% ukupne mase uzorka nakon grijanja od oko 25 do oko 120 "€.
the tyrosine at position 7 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, F, H, I, L, M, N, P, S, T, V, and W; 
tirozin na položaju 7 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, F, H, I, L, M, N, P, S, T, V i W;
13), said residues of the sequence optionally including side chain protection. 
13), navedeni ostaci sekvence po izboru uključuju zaštitu bočnog lanca.
Aqueous suspension according to any of claims 1 to 16, characterized in that step d) and addition of said water-soluble salt preferably take place in a stirred reactor under stirring conditions such as to develop an essentially laminar flow. 
Postupak prema bilo kojem od zahtjeva 1 do 17, naznačen time da se korak d) i dodavanje navedene kiseline topive u vodi poželjno odvija u reaktoru za miješanje pod uvjetima miješanja koji su potrebni da bi se razvio u osnovi laminarni tok.
Four adenosine receptors have been cloned and characterized, A1, A2A, A2B and A3 (Fredholm et al, 1994, Pharmac. Rev., 46, 143-156). 
Četiri adenozinska receptora su klonirana i karakterizirana, A,, A2a, A2p i A3 (Fredholm et al, 1994, Pharmac.Rev., 46, 143-156).
The organic layer was washed four times with brine, dried over MgSO4, and the volatiles evaporated to give N-a-(tert-butoxycarbonyl)-O-a-tert-butyl-L-Y-glutamyl-S-(4-biphenylylmethyl)-L-cysteinyl-D-cyclohexylglycine as a brown oil. 
Organski spoj ispran je četiri puta sa slanom otopinom, osušen preko MgSO,, a uparavanjem je dobiveno smeđe ulje.
The method according to claim 4, wherein the biomass comprises sugar, or starch, or a mixture of sugar and starch. 
7. > Postupak u skladu s patentnim zahtjevom 6, naznačen time što je biomasa bogata šećerom, škrobom, ili njihovom smjesom.
The compound for use of claim 1, wherein the disease or disorder is lung lymphoma, esophageal lymphoma, stomach lymphoma, small bowel lymphoma, kidney lymphoma, bone malignant lymphoma, or hematologic lymphoma. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da bolest ili poremećaj je višestruki oblik glioblastoma.
Assays of enzyme activity were performed at 37° C. by monitoring changes in UV absorbance at 340 nm of a solution containing 50 mM N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (pH 7.0), 1 mM EDTA, 75 uM 2-mercaptoethanol, 0.1% bovine serum albumin, 20 uM dihydrofolate, and 100 uM NADPH. 
Ispitivanja enzimske aktivnosti provedena su pri 37 *C praćenjem promjena u UV apsorbanciji pri 340 nm otopine koja sadrži 50 mM N-tris(hidroksimetil)metil-2-aminoctansulfonske kiseline (pH 7,0), 1 mM EDTA, 75 uM 2-merkaptoctanola, 0,1 % albumina goveđeg seruma, 20 UM dihidrofolata, i 100 uM NADPH.
The method of claim 1, wherein the dexmedetomidine is administered before or after surgery. 
Deksmedetomidin, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se deksmedetomidin primjenjuje nakon kirurškog zahvata.